Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer

Simple Summary Patients with locally advanced rectal cancer have been treated with chemoradiotherapy followed by surgery, which results in variable therapy response. To date, there is a lack of established predictive biomarkers to distinguish responsive from non-responsive patients. Therefore, patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2020-10, Vol.12 (11), p.3079, Article 3079
Hauptverfasser: do Canto, Luisa Matos, Barros-Filho, Mateus Camargo, Rainho, Claudia Aparecida, Marinho, Diogo, Kupper, Bruna Elisa Catin, Begnami, Maria Dirlei Ferreira de Souza, Scapulatempo-Neto, Cristovam, Havelund, Birgitte Mayland, Lindebjerg, Jan, Marchi, Fabio Albuquerque, Baumbach, Jan, Aguiar, Samuel, Rogatto, Silvia Regina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 11
container_start_page 3079
container_title Cancers
container_volume 12
creator do Canto, Luisa Matos
Barros-Filho, Mateus Camargo
Rainho, Claudia Aparecida
Marinho, Diogo
Kupper, Bruna Elisa Catin
Begnami, Maria Dirlei Ferreira de Souza
Scapulatempo-Neto, Cristovam
Havelund, Birgitte Mayland
Lindebjerg, Jan
Marchi, Fabio Albuquerque
Baumbach, Jan
Aguiar, Samuel
Rogatto, Silvia Regina
description Simple Summary Patients with locally advanced rectal cancer have been treated with chemoradiotherapy followed by surgery, which results in variable therapy response. To date, there is a lack of established predictive biomarkers to distinguish responsive from non-responsive patients. Therefore, patients can be overtreated resulting in unnecessary toxicity, or therapy changes can occur later when the cancer is more aggressive. We used pre-treatment biopsies to evaluate changes in DNA methylation that could predict the chemoradiotherapy response. Data from an external dataset were used to confirm our findings. We identified and validated a classifier, composed of three candidates, that was able to distinguish responders from non-responders. The genomic context of our biomarkers was explored, giving evidence that they play a role in regulating gene expression. The biomarkers herein described can be easily evaluated in the clinical practice and can help to guide rectal cancer patients' treatment by identifying responders and non-responders. The treatment for locally advanced rectal carcinomas (LARC) is based on neoadjuvant chemoradiotherapy (nCRT) and surgery, which results in pathological complete response (pCR) in up to 30% of patients. Since epigenetic changes may influence response to therapy, we aimed to identify DNA methylation markers predictive of pCR in LARC patients treated with nCRT. We used high-throughput DNA methylation analysis of 32 treatment-naive LARC biopsies and five normal rectal tissues to explore the predictive value of differentially methylated (DM) CpGs. External validation was carried out with The Cancer Genome Atlas-Rectal Adenocarcinoma (TCGA-READ 99 cases). A classifier based on three-CpGs DM (linked to OBSL1, GPR1, and INSIG1 genes) was able to discriminate pCR from incomplete responders with high sensitivity and specificity. The methylation levels of the selected CpGs confirmed the predictive value of our classifier in 77 LARCs evaluated by bisulfite pyrosequencing. Evaluation of external datasets (TCGA-READ, GSE81006, GSE75546, and GSE39958) reproduced our results. As the three CpGs were mapped near to regulatory elements, we performed an integrative analysis in regions associated with predicted cis-regulatory elements. A positive and inverse correlation between DNA methylation and gene expression was found in two CpGs. We propose a novel predictive tool based on three CpGs potentially useful for pretreatment screening of LARC pa
doi_str_mv 10.3390/cancers12113079
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3390_cancers12113079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2454650726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-b5187bfd7008811e58df80a6cff3b3f203c83743b06c35b9355e4bd1484d23523</originalsourceid><addsrcrecordid>eNqNkUtv1DAUhSMEolXpmq2XSGioHT_ibJBG4VGkoSBU1pFjXzOuMnawnUGR-PH1zFQVsMIbX-uec3ztr6peEvyG0hZfaeU1xERqQihu2ifVeY2beiVEy57-UZ9Vlynd4bIoJY1onldnpcC8IeS8-t2F3RRhCz65PaC1V-OSXELBonc3a_QZ8nYZVXbBI-UN-hrBOH08FsU3SFPwCVAO6AaCMnfzXvl8u4WopgU5jzZBq3Fc0NrsD8OaYtFZjag7jv6iembVmODyYb-ovn94f9tdrzZfPn7q1puVZlTk1cCJbAZrGoylJAS4NFZiJbS1dKC2xlRL2jA6YKEpH1rKObDBECaZqSmv6UX19pQ7zcMOjAafoxr7KbqdiksflOv_7ni37X-Efd-IFlNJS8Crh4AYfs6Qcr9zScM4Kg9hTn3NOBO8fLgo0quTVMeQUgT7eA3B_QFb_w-24nh9cvyCIdikHZT-o6tg4-VFTPIDQVLU8v_VnctHdl2Yfab3WD2teQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454650726</pqid></control><display><type>article</type><title>Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Web of Science - Science Citation Index Expanded - 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>PubMed Central</source><creator>do Canto, Luisa Matos ; Barros-Filho, Mateus Camargo ; Rainho, Claudia Aparecida ; Marinho, Diogo ; Kupper, Bruna Elisa Catin ; Begnami, Maria Dirlei Ferreira de Souza ; Scapulatempo-Neto, Cristovam ; Havelund, Birgitte Mayland ; Lindebjerg, Jan ; Marchi, Fabio Albuquerque ; Baumbach, Jan ; Aguiar, Samuel ; Rogatto, Silvia Regina</creator><creatorcontrib>do Canto, Luisa Matos ; Barros-Filho, Mateus Camargo ; Rainho, Claudia Aparecida ; Marinho, Diogo ; Kupper, Bruna Elisa Catin ; Begnami, Maria Dirlei Ferreira de Souza ; Scapulatempo-Neto, Cristovam ; Havelund, Birgitte Mayland ; Lindebjerg, Jan ; Marchi, Fabio Albuquerque ; Baumbach, Jan ; Aguiar, Samuel ; Rogatto, Silvia Regina</creatorcontrib><description>Simple Summary Patients with locally advanced rectal cancer have been treated with chemoradiotherapy followed by surgery, which results in variable therapy response. To date, there is a lack of established predictive biomarkers to distinguish responsive from non-responsive patients. Therefore, patients can be overtreated resulting in unnecessary toxicity, or therapy changes can occur later when the cancer is more aggressive. We used pre-treatment biopsies to evaluate changes in DNA methylation that could predict the chemoradiotherapy response. Data from an external dataset were used to confirm our findings. We identified and validated a classifier, composed of three candidates, that was able to distinguish responders from non-responders. The genomic context of our biomarkers was explored, giving evidence that they play a role in regulating gene expression. The biomarkers herein described can be easily evaluated in the clinical practice and can help to guide rectal cancer patients' treatment by identifying responders and non-responders. The treatment for locally advanced rectal carcinomas (LARC) is based on neoadjuvant chemoradiotherapy (nCRT) and surgery, which results in pathological complete response (pCR) in up to 30% of patients. Since epigenetic changes may influence response to therapy, we aimed to identify DNA methylation markers predictive of pCR in LARC patients treated with nCRT. We used high-throughput DNA methylation analysis of 32 treatment-naive LARC biopsies and five normal rectal tissues to explore the predictive value of differentially methylated (DM) CpGs. External validation was carried out with The Cancer Genome Atlas-Rectal Adenocarcinoma (TCGA-READ 99 cases). A classifier based on three-CpGs DM (linked to OBSL1, GPR1, and INSIG1 genes) was able to discriminate pCR from incomplete responders with high sensitivity and specificity. The methylation levels of the selected CpGs confirmed the predictive value of our classifier in 77 LARCs evaluated by bisulfite pyrosequencing. Evaluation of external datasets (TCGA-READ, GSE81006, GSE75546, and GSE39958) reproduced our results. As the three CpGs were mapped near to regulatory elements, we performed an integrative analysis in regions associated with predicted cis-regulatory elements. A positive and inverse correlation between DNA methylation and gene expression was found in two CpGs. We propose a novel predictive tool based on three CpGs potentially useful for pretreatment screening of LARC patients and guide the selection of treatment modality.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers12113079</identifier><identifier>PMID: 33105711</identifier><language>eng</language><publisher>BASEL: Mdpi</publisher><subject>Life Sciences &amp; Biomedicine ; Oncology ; Science &amp; Technology</subject><ispartof>Cancers, 2020-10, Vol.12 (11), p.3079, Article 3079</ispartof><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>13</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000593548500001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c436t-b5187bfd7008811e58df80a6cff3b3f203c83743b06c35b9355e4bd1484d23523</citedby><cites>FETCH-LOGICAL-c436t-b5187bfd7008811e58df80a6cff3b3f203c83743b06c35b9355e4bd1484d23523</cites><orcidid>0000-0003-3893-5269 ; 0000-0003-3476-727X ; 0000-0002-6566-5367 ; 0000-0002-0285-1162 ; 0000-0002-0282-0462 ; 0000-0001-5815-8423 ; 0000-0001-9095-9431 ; 0000-0002-2055-4241 ; 0000-0003-4637-5687</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690383/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690383/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,28255,53798,53800</link.rule.ids></links><search><creatorcontrib>do Canto, Luisa Matos</creatorcontrib><creatorcontrib>Barros-Filho, Mateus Camargo</creatorcontrib><creatorcontrib>Rainho, Claudia Aparecida</creatorcontrib><creatorcontrib>Marinho, Diogo</creatorcontrib><creatorcontrib>Kupper, Bruna Elisa Catin</creatorcontrib><creatorcontrib>Begnami, Maria Dirlei Ferreira de Souza</creatorcontrib><creatorcontrib>Scapulatempo-Neto, Cristovam</creatorcontrib><creatorcontrib>Havelund, Birgitte Mayland</creatorcontrib><creatorcontrib>Lindebjerg, Jan</creatorcontrib><creatorcontrib>Marchi, Fabio Albuquerque</creatorcontrib><creatorcontrib>Baumbach, Jan</creatorcontrib><creatorcontrib>Aguiar, Samuel</creatorcontrib><creatorcontrib>Rogatto, Silvia Regina</creatorcontrib><title>Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer</title><title>Cancers</title><addtitle>CANCERS</addtitle><description>Simple Summary Patients with locally advanced rectal cancer have been treated with chemoradiotherapy followed by surgery, which results in variable therapy response. To date, there is a lack of established predictive biomarkers to distinguish responsive from non-responsive patients. Therefore, patients can be overtreated resulting in unnecessary toxicity, or therapy changes can occur later when the cancer is more aggressive. We used pre-treatment biopsies to evaluate changes in DNA methylation that could predict the chemoradiotherapy response. Data from an external dataset were used to confirm our findings. We identified and validated a classifier, composed of three candidates, that was able to distinguish responders from non-responders. The genomic context of our biomarkers was explored, giving evidence that they play a role in regulating gene expression. The biomarkers herein described can be easily evaluated in the clinical practice and can help to guide rectal cancer patients' treatment by identifying responders and non-responders. The treatment for locally advanced rectal carcinomas (LARC) is based on neoadjuvant chemoradiotherapy (nCRT) and surgery, which results in pathological complete response (pCR) in up to 30% of patients. Since epigenetic changes may influence response to therapy, we aimed to identify DNA methylation markers predictive of pCR in LARC patients treated with nCRT. We used high-throughput DNA methylation analysis of 32 treatment-naive LARC biopsies and five normal rectal tissues to explore the predictive value of differentially methylated (DM) CpGs. External validation was carried out with The Cancer Genome Atlas-Rectal Adenocarcinoma (TCGA-READ 99 cases). A classifier based on three-CpGs DM (linked to OBSL1, GPR1, and INSIG1 genes) was able to discriminate pCR from incomplete responders with high sensitivity and specificity. The methylation levels of the selected CpGs confirmed the predictive value of our classifier in 77 LARCs evaluated by bisulfite pyrosequencing. Evaluation of external datasets (TCGA-READ, GSE81006, GSE75546, and GSE39958) reproduced our results. As the three CpGs were mapped near to regulatory elements, we performed an integrative analysis in regions associated with predicted cis-regulatory elements. A positive and inverse correlation between DNA methylation and gene expression was found in two CpGs. We propose a novel predictive tool based on three CpGs potentially useful for pretreatment screening of LARC patients and guide the selection of treatment modality.</description><subject>Life Sciences &amp; Biomedicine</subject><subject>Oncology</subject><subject>Science &amp; Technology</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqNkUtv1DAUhSMEolXpmq2XSGioHT_ibJBG4VGkoSBU1pFjXzOuMnawnUGR-PH1zFQVsMIbX-uec3ztr6peEvyG0hZfaeU1xERqQihu2ifVeY2beiVEy57-UZ9Vlynd4bIoJY1onldnpcC8IeS8-t2F3RRhCz65PaC1V-OSXELBonc3a_QZ8nYZVXbBI-UN-hrBOH08FsU3SFPwCVAO6AaCMnfzXvl8u4WopgU5jzZBq3Fc0NrsD8OaYtFZjag7jv6iembVmODyYb-ovn94f9tdrzZfPn7q1puVZlTk1cCJbAZrGoylJAS4NFZiJbS1dKC2xlRL2jA6YKEpH1rKObDBECaZqSmv6UX19pQ7zcMOjAafoxr7KbqdiksflOv_7ni37X-Efd-IFlNJS8Crh4AYfs6Qcr9zScM4Kg9hTn3NOBO8fLgo0quTVMeQUgT7eA3B_QFb_w-24nh9cvyCIdikHZT-o6tg4-VFTPIDQVLU8v_VnctHdl2Yfab3WD2teQ</recordid><startdate>20201022</startdate><enddate>20201022</enddate><creator>do Canto, Luisa Matos</creator><creator>Barros-Filho, Mateus Camargo</creator><creator>Rainho, Claudia Aparecida</creator><creator>Marinho, Diogo</creator><creator>Kupper, Bruna Elisa Catin</creator><creator>Begnami, Maria Dirlei Ferreira de Souza</creator><creator>Scapulatempo-Neto, Cristovam</creator><creator>Havelund, Birgitte Mayland</creator><creator>Lindebjerg, Jan</creator><creator>Marchi, Fabio Albuquerque</creator><creator>Baumbach, Jan</creator><creator>Aguiar, Samuel</creator><creator>Rogatto, Silvia Regina</creator><general>Mdpi</general><general>MDPI</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3893-5269</orcidid><orcidid>https://orcid.org/0000-0003-3476-727X</orcidid><orcidid>https://orcid.org/0000-0002-6566-5367</orcidid><orcidid>https://orcid.org/0000-0002-0285-1162</orcidid><orcidid>https://orcid.org/0000-0002-0282-0462</orcidid><orcidid>https://orcid.org/0000-0001-5815-8423</orcidid><orcidid>https://orcid.org/0000-0001-9095-9431</orcidid><orcidid>https://orcid.org/0000-0002-2055-4241</orcidid><orcidid>https://orcid.org/0000-0003-4637-5687</orcidid></search><sort><creationdate>20201022</creationdate><title>Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer</title><author>do Canto, Luisa Matos ; Barros-Filho, Mateus Camargo ; Rainho, Claudia Aparecida ; Marinho, Diogo ; Kupper, Bruna Elisa Catin ; Begnami, Maria Dirlei Ferreira de Souza ; Scapulatempo-Neto, Cristovam ; Havelund, Birgitte Mayland ; Lindebjerg, Jan ; Marchi, Fabio Albuquerque ; Baumbach, Jan ; Aguiar, Samuel ; Rogatto, Silvia Regina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-b5187bfd7008811e58df80a6cff3b3f203c83743b06c35b9355e4bd1484d23523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Life Sciences &amp; Biomedicine</topic><topic>Oncology</topic><topic>Science &amp; Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>do Canto, Luisa Matos</creatorcontrib><creatorcontrib>Barros-Filho, Mateus Camargo</creatorcontrib><creatorcontrib>Rainho, Claudia Aparecida</creatorcontrib><creatorcontrib>Marinho, Diogo</creatorcontrib><creatorcontrib>Kupper, Bruna Elisa Catin</creatorcontrib><creatorcontrib>Begnami, Maria Dirlei Ferreira de Souza</creatorcontrib><creatorcontrib>Scapulatempo-Neto, Cristovam</creatorcontrib><creatorcontrib>Havelund, Birgitte Mayland</creatorcontrib><creatorcontrib>Lindebjerg, Jan</creatorcontrib><creatorcontrib>Marchi, Fabio Albuquerque</creatorcontrib><creatorcontrib>Baumbach, Jan</creatorcontrib><creatorcontrib>Aguiar, Samuel</creatorcontrib><creatorcontrib>Rogatto, Silvia Regina</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>do Canto, Luisa Matos</au><au>Barros-Filho, Mateus Camargo</au><au>Rainho, Claudia Aparecida</au><au>Marinho, Diogo</au><au>Kupper, Bruna Elisa Catin</au><au>Begnami, Maria Dirlei Ferreira de Souza</au><au>Scapulatempo-Neto, Cristovam</au><au>Havelund, Birgitte Mayland</au><au>Lindebjerg, Jan</au><au>Marchi, Fabio Albuquerque</au><au>Baumbach, Jan</au><au>Aguiar, Samuel</au><au>Rogatto, Silvia Regina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer</atitle><jtitle>Cancers</jtitle><stitle>CANCERS</stitle><date>2020-10-22</date><risdate>2020</risdate><volume>12</volume><issue>11</issue><spage>3079</spage><pages>3079-</pages><artnum>3079</artnum><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Simple Summary Patients with locally advanced rectal cancer have been treated with chemoradiotherapy followed by surgery, which results in variable therapy response. To date, there is a lack of established predictive biomarkers to distinguish responsive from non-responsive patients. Therefore, patients can be overtreated resulting in unnecessary toxicity, or therapy changes can occur later when the cancer is more aggressive. We used pre-treatment biopsies to evaluate changes in DNA methylation that could predict the chemoradiotherapy response. Data from an external dataset were used to confirm our findings. We identified and validated a classifier, composed of three candidates, that was able to distinguish responders from non-responders. The genomic context of our biomarkers was explored, giving evidence that they play a role in regulating gene expression. The biomarkers herein described can be easily evaluated in the clinical practice and can help to guide rectal cancer patients' treatment by identifying responders and non-responders. The treatment for locally advanced rectal carcinomas (LARC) is based on neoadjuvant chemoradiotherapy (nCRT) and surgery, which results in pathological complete response (pCR) in up to 30% of patients. Since epigenetic changes may influence response to therapy, we aimed to identify DNA methylation markers predictive of pCR in LARC patients treated with nCRT. We used high-throughput DNA methylation analysis of 32 treatment-naive LARC biopsies and five normal rectal tissues to explore the predictive value of differentially methylated (DM) CpGs. External validation was carried out with The Cancer Genome Atlas-Rectal Adenocarcinoma (TCGA-READ 99 cases). A classifier based on three-CpGs DM (linked to OBSL1, GPR1, and INSIG1 genes) was able to discriminate pCR from incomplete responders with high sensitivity and specificity. The methylation levels of the selected CpGs confirmed the predictive value of our classifier in 77 LARCs evaluated by bisulfite pyrosequencing. Evaluation of external datasets (TCGA-READ, GSE81006, GSE75546, and GSE39958) reproduced our results. As the three CpGs were mapped near to regulatory elements, we performed an integrative analysis in regions associated with predicted cis-regulatory elements. A positive and inverse correlation between DNA methylation and gene expression was found in two CpGs. We propose a novel predictive tool based on three CpGs potentially useful for pretreatment screening of LARC patients and guide the selection of treatment modality.</abstract><cop>BASEL</cop><pub>Mdpi</pub><pmid>33105711</pmid><doi>10.3390/cancers12113079</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0003-3893-5269</orcidid><orcidid>https://orcid.org/0000-0003-3476-727X</orcidid><orcidid>https://orcid.org/0000-0002-6566-5367</orcidid><orcidid>https://orcid.org/0000-0002-0285-1162</orcidid><orcidid>https://orcid.org/0000-0002-0282-0462</orcidid><orcidid>https://orcid.org/0000-0001-5815-8423</orcidid><orcidid>https://orcid.org/0000-0001-9095-9431</orcidid><orcidid>https://orcid.org/0000-0002-2055-4241</orcidid><orcidid>https://orcid.org/0000-0003-4637-5687</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2020-10, Vol.12 (11), p.3079, Article 3079
issn 2072-6694
2072-6694
language eng
recordid cdi_crossref_primary_10_3390_cancers12113079
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central
subjects Life Sciences & Biomedicine
Oncology
Science & Technology
title Comprehensive Analysis of DNA Methylation and Prediction of Response to NeoadjuvantTherapy in Locally Advanced Rectal Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T19%3A50%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comprehensive%20Analysis%20of%20DNA%20Methylation%20and%20Prediction%20of%20Response%20to%20NeoadjuvantTherapy%20in%20Locally%20Advanced%20Rectal%20Cancer&rft.jtitle=Cancers&rft.au=do%20Canto,%20Luisa%20Matos&rft.date=2020-10-22&rft.volume=12&rft.issue=11&rft.spage=3079&rft.pages=3079-&rft.artnum=3079&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers12113079&rft_dat=%3Cproquest_cross%3E2454650726%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2454650726&rft_id=info:pmid/33105711&rfr_iscdi=true